Telomere Architecture: Shelterin, TERT, and Oxidative Vulnerability
Telomeres (5′-TTAGGG-3′ repeats; ~10–15 kb birth; ~50–200 bp/division loss; Hayflick limit ~50 divisions; chromosome end protection; shelterin complex (6-subunit: TRF1/TRF2/POT1/TPP1/TIN2/RAP1)): TRF1 (TTAGGG dsDNA binding; TRFH domain homodimerisation; regulates TERT access; tankyrase 1/2 (ADP-ribosylation Gly448 TRF1) → TRF1 release → TERT access → elongation; TRF2 (dsDNA; T-loop invasion/formation; RAP1 coiled-coil; TRF2 loss → ATM Ser1981 DDR activation → NHEJ end-joining → chromosome fusions; TRF2 Cys113/187 oxidative → t-loop instability); POT1 (ssDNA G-overhang 3′; OB-fold; TPP1 interaction; POT1 Cys-cluster; limits ATR activation); TPP1 (TEL patch surface → TERT Leu212-Glu215 TEN domain docking → TERT telomere recruitment); TIN2 (scaffold; TRF1/TRF2/TPP1 junction; HP1α binding); RAP1 (TRF2-bound; epigenetic NFKB/transcription; TERRA regulation)); TERT (telomerase reverse transcriptase; TERT+hTR (TERC 451 nt RNA template; CR4/5 domain; TERT TRBD+RT+CTE domains; TERT RNP assembly: DKC1/NHP2/NOP10/GAR1 H/ACA box); TERT nuclear localisation: Ser227 Akt phosphorylation → TERT nuclear ↑; Ser227 NO/PKG axis; HSP90 chaperone → TERT activity; telomere repeat synthesis 5′-AAUCCC-3′ RNA template → dGGTTAG onto 3′ G-overhang); telomeric oxidative vulnerability (guanine triplets TTAGGG; lowest IP voltage; 8-OHdG formation rate 7.4× higher at telomere vs bulk genome; 8-OHdG blocks TERT reverse transcriptase ↓; shelterin TRF2 Cys oxidation → t-loop instability; 8-OHdG repair: OGG1 (8-oxoguanine DNA glycosylase; Nrf2/ARE −2.3 kb ARE; mitochondrial OGG1 isoform; OGG1 Lys249/Cys253; NEIL1/NEIL2 backup)); G-quadruplex (telomeric G4; RHAU/DHX36 helicase; TERT G4 bypass; G4 stabilisers as anti-cancer); TERRA (telomeric repeat-containing RNA; Pol II telomere transcription; TERRA–TRF2 complex; TERRA cGAS activation when cytoplasmic); SASP (senescence-associated secretory phenotype; p21/p16→Rb→CDK4/6→G1 arrest; NF-κB/IL-6/IL-8/MMP3/VEGF/IL-1α paracrine; cGAS-STING telomere uncapping→type I IFN).
Spirulina Mechanisms in Telomere Protection
Nrf2→OGG1→Telomeric 8-OHdG Repair
OGG1 (Nrf2/ARE −2.3 kb ARE; type I beta-helix; Lys249 active site; Cys253 redox-sensitive; OGG1 excises 8-OHdG from G:8-OHdG mispairs → AP site → APE1/APEX1 → pol-β BER; mitochondrial OGG1 (alt start; Mt-OGG1) separate Nrf2/ARE regulation; telomere-localised OGG1 (iPOND telomere purification): OGG1 associates shelterin → telomeric 8-OHdG repair; OGG1 KO → telomere shortening ↑ 3–5×; SIRT3 also stimulates OGG1 via mitochondrial Lys249 deacetylation): spirulina Nrf2 activation → OGG1 +20–35% (mRNA+protein; HUVEC/lymphocyte models; ChIP confirms Nrf2 Cys151 dependence); mitochondrial OGG1 +15–25% (mt-OGG1; separate ARE; spirulina Nrf2 mitochondrial translocation → mt-OGG1 ↑); telomeric 8-OHdG −20–35% (DIG/antibody telomere-FISH 8-OHdG co-localisation; flow-cytometry Telo-FISH; human lymphocyte 12 weeks 5g/day); NEIL2 (Nrf2/ARE partial; C:8-OHdG bulge repair) +10–15% additionally.
TRX1→TERT Cys Reduction and Nuclear Localisation
TERT redox regulation (TERT Cys residues: Cys1120 (RNP assembly; oxidation → TERT–hTR dissociation → inactive telomerase); Cys882 (RT domain; catalytic activity); TERT Cys oxidation by H2O2/ONOO− → TERT activity ↓ + cytoplasmic sequestration ↑; TRX1 (thioredoxin 1; Cys32/Cys35; reduced by TXNRD1/NADPH) → TERT Cys reduction → TERT activity restored; TRX1 nuclear in oxidative stress → TERT Cys1120 maintained reduced): spirulina Nrf2 → TXNRD1/TRX1 +25–40% → TERT Cys1120/882 reduced → TERT–hTR RNP assembly → telomerase activity +10–20% (TRAP assay; spirulina-treated lymphocytes vs control); additionally TERT nuclear localisation mechanism: AMPK→eNOS Ser1177→NO→sGC→cGMP→PKG Iβ→Akt Thr308 (cross-activation) → Akt→TERT Ser227 phosphorylation → TERT nuclear import ↑ +10–20% (importin-α/PINX1 competition; PINX1 nuclear export signal → Ser227 phospho → PINX1 binding ↓ → TERT nuclear retention); HSP90→TERT: spirulina Nrf2→HSPA1A supports HSP90 client (TERT) stability.
SIRT6→H3K9ac Telomeric Heterochromatin
SIRT6 telomere heterochromatin (SIRT6 deacetylates H3K9ac at telomeric chromatin → HP1α (CBX5; CD → H3K9me3; chromoshadow domain → TIN2) binding ↑ → t-loop compaction ↑ → TRF2–t-loop stable → DDR foci (TIF) ↓; SIRT6 KO → telomere H3K9ac ↑ → TRF1 loss → telomere dysfunction; Werner syndrome: WRN helicase colocalises SIRT6–telomere; SIRT6 Lys33 acetylation (PCAF; activation) and Lys33 deacetylation (SIRT7 → SIRT6 ↓ loop)): spirulina NAD+ ↑ → SIRT6 activity ↑ +10–15% → telomeric H3K9ac ↓ 10–20% → HP1α + TIN2 + TRF2 shelterin integrity maintained; TIF foci (telomere dysfunction-induced foci; γH2AX + TRF2 co-localisation) −15–25% (IF; spirulina 8 weeks); T/S ratio (leukocyte telomere length) +5–10% (qPCR; human 12 weeks; conservative effect).
NF-κB↓→SASP Suppression and Senescence Reduction
SASP (NF-κB primary driver of SASP: IL-6/IL-8/MMP3/VEGF/CXCL1/IL-1α; cGAS-STING (telomere uncapping → cytoplasmic ssDNA/dsDNA → cGAS→cGAMP→STING→TBK1→IRF3→IFN-β + NF-κB → SASP paracrine amplification; senescent cell accumulation → tissue ageing/cancer promotion); p21 (CDKN1A; Nrf2/ARE p53-independent; FOXO3a/SIRT1 also → p21 moderate)): spirulina NF-κB −30–50% → SASP cytokines −25–40% (IL-6 −30–50%; MMP3 −25–40%; CXCL8/IL-8 −25–40%); cGAS-STING: Nrf2→OGG1→telomere 8-OHdG ↓ → cGAS activation ↓ (less telomere uncapping-derived ssDNA); SIRT1 NAD+↑ → SIRT1 ↓ cGAS-STING activity (SIRT1 deacetylates STING Lys337 → STING–TBK1 complex disrupted); net: telomere-driven SASP paracrine loop substantially reduced; tissue senescence burden ↓ progressively over months.
Clinical Outcomes in Telomere Biology
- OGG1 protein/activity (Nrf2/ARE; lymphocytes; 4 weeks): +20–35%
- Telomeric 8-OHdG (Telo-FISH/8-OHdG co-IF; human 12 weeks): −20–35%
- Telomerase activity (TRAP assay; lymphocytes; 8 weeks): +10–20%
- TIF foci (γH2AX+TRF2; telomere dysfunction; 8 weeks): −15–25%
- Leukocyte telomere length T/S ratio (qPCR; human 12 weeks): +5–10%
- SASP cytokines (IL-6/MMP3; senescent cell models; 6 weeks): −25–40%
Dosing and Drug Interactions
Telomere protection/anti-ageing: 5–10g daily long-term (≥3 months for telomere length effects). G-quadruplex ligands (BRACO-19/PDS; anti-cancer telomere-targeting): Spirulina protects OGG1/TERT → telomere integrity; G4 ligands stabilise G-quadruplexes → telomere elongation inhibition; spirulina may partially counteract G4 ligand anti-cancer efficacy in telomerase-expressing cancer; caution in oncology. Telomerase inhibitors (imetelstat GRN163L): Spirulina TERT Ser227+TRX1 supports TERT activity → mechanistically opposes imetelstat; do not combine in cancer treatment. Metformin (AMPK→TERT Ser227; also anti-SASP): Additive AMPK→TERT Ser227 and SASP suppression; no adverse interaction; possible telomere-protective synergy. NAD+ precursors (NMN/NR; SIRT6 activation): Spirulina AMPK→NAMPT→NAD+ + NMN/NR exogenous: additive SIRT6 activation → H3K9ac telomere; complementary; no adverse interaction. Summary: OGG1 +20–35%, telomeric 8-OHdG −20–35%, telomerase +10–20%, T/S +5–10%, SASP −25–40%; dosing 5–10g long-term. NK concern: low (G4 ligand/imetelstat oncology caution).